Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, TDS, PET, FVT

Kindred Biosciences to Present at Jefferies 2018 Global Healthcare Conference and 8th Annual LD Micro Invitational Conference


SAN FRANCISCO, May 29, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the 8th Annual LD Micro Invitational Conference taking place June 4th-6th in Bel Air, CA and at the Jefferies 2018 Global Healthcare Conference taking place June 5th-8th in New York.

Kindred Biosciences, Inc. Logo

Richard Chin, M.D., President and Chief Executive Officer, will present and be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, including the approval of KindredBio's first product, key therapeutic programs in development, and upcoming milestones.

Presentation Details:

8th Annual LD Micro Invitational Conference

Date: Tuesday, June 5, 2018

Time: 7:30 ? 8 AM PDT

Location: Luxe Sunset Boulevard Hotel, Track 2

Webcast URL: Click here

Jefferies 2018 Global Healthcare Conference

Date: Friday, June 8, 2018

Time: 2 ? 2.25 PM EDT

Location: Grand Hyatt, NY, Ballroom IV

Webcast URL: Click here

An archived version of the above webcasts will be available for 30 days on the Company's website.

About Kindred Biosciences 
Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. KindredBio's first approved drug is Mirataztm (mirtazapine transdermal ointment) for the management of weight loss in cats.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Contact
Russell Radefeld 
KindredBio
[email protected] 
(650) 701-7904  

SOURCE Kindred Biosciences, Inc.


These press releases may also interest you

at 09:15
Vibrant Wellness, a leader in specialized diagnostics and personalized health tools, announced today that its Tickborne Testing received approval from The Wadsworth Center, part of the New York State Department of Health.This approval enables Vibrant...

at 09:00
Guidewire announced that Guidewire PartnerConnect Consulting and Global Premier partner, Ernst & Young LLP (EY), has achieved the global Migration Acceleration Specialization. Partners who have earned this specialization have demonstrated the...

at 09:00
The Commerce Casino & Hotel, home to the largest poker room in the world, proudly announces an exciting partnership with the richest, most prestigious, and longest-running poker series ? the World Series of Poker® (WSOP®). This collaboration...

at 09:00
The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp , a global leader of innovative diagnostic and biopharma laboratory services, to serve as its...

at 09:00
Rex 3 recently opened its doors to students from Florida Atlantic University (FAU) for Rex 3's 11th Annual 101 Printing Tour, reinforcing its commitment to community engagement and education in the printing industry. This tour provided students with...

at 09:00
GigaMedia Limited today announced its unaudited financial results for the fourth quarter and full year of 2023. Highlights For 2023, GigaMedia reported revenues of $4.3 million, with a gross profit of $2.4 million, an operating loss of $3.2 million...



News published on and distributed by: